Loading
NASDAQHealthcareBiotechnology
Latest quote
$4.59
−$0.08 · -1.71%
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Previous close
$4.59
−$0.08 · -1.71%
After-hours
$4.60
+$0.01 · +0.22%
Sep 11, 7:57 PM ET
Regular session · ET · Market data may be delayed.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Day range
Current $4.59
52-week range
Current $4.59
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
63
Undervalued
Sentiment
70
Bullish
Risk
51
Elevated Risk
Momentum
73
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Day range
Current $4.59
52-week range
Current $4.59
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 12.14M USD | 7M USD | — | — | — |
| Cost of goods sold | 1.71M USD | — | — | — | — |
| Gross profit | 10.43M USD | 7M USD | — | — | — |
| Research and development | 94.3M USD | 118M USD | 103.39M USD | 92.89M USD | 86.78M USD |
| Selling, general, and administrative | 22.41M USD | 28.72M USD | 28.88M USD | 30.65M USD | 26.96M USD |
| Operating expenses | 115M USD | 146.71M USD | 132.28M USD | 123.54M USD | 113.74M USD |
| Depreciation and amortization | 1.71M USD | 1.77M USD | 1.17M USD | 1.32M USD | 915K USD |
| Operating income | −104.57M USD | −139.71M USD | −132.28M USD | −123.54M USD | −113.74M USD |
| Net income | −99.5M USD | −127.17M USD | −121.83M USD | −115.44M USD | −111.69M USD |
Company facts updated Sep 12, 2026.
Third-party consensus; not a GoAI recommendation.
Average target
$8.00
74.29% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI6.96M0.00%2.3T USD0.03%$376.31+0.82%
iShares Russell 2000 ETFIWM3.51M0.00%77.55B USD0.19%$288.89+0.41%
Vanguard Extended Market ETFVXF2.11M0.00%93.7B USD0.05%$237.76+0.68%
iShares Russell 2000 Growth ETFIWO1.33M0.01%14.32B USD0.24%$367.63+0.54%
Vanguard Russell 2000 ETFVTWO715.26K0.00%17.4B USD0.06%$116.76+0.36%
iShares Micro-Cap ETFIWC470.66K0.03%1.44B USD0.60%$190.84+0.39%
Vanguard Russell 2000 Growth ETFVTWG138.01K0.01%1.7B USD0.06%$268.4+0.57%
Invesco Russell 2000 Dynamic Multifactor ETFOMFS91.8K0.03%276.02M USD0.39%$51.57+0.33%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGInvesco Russell 2000 Dynamic Multifactor ETFOMFSAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
